Traditional Drug Pipeline Monthly Update: November 2022

Critical updates in an ever changing environment

November 18, 2022
This monthly pipeline wrap-up provides a review of newly approved traditional drugs, recent drug launches, generic updates, new indications and news of note on drugs in the approval process.

See separate articles for pipeline information on specialty drugs.

New Drug Information

  • Rezvoglar® (insulin glargine-aglr): The U.S. Food and Drug Administration (FDA) approved the second interchangeable biosimilar insulin product to Lantus® (insulin glargine), Eli Lilly’s Rezvoglar® (insulin glargine-aglr).1Rezvoglar is a long-acting human insulin analog indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus. FDA previously approved Rezvoglar as a biosimilar to Lantus on December 17, 2021.

Generic Drug Information

  • Daliresp® (roflumilast tablet): Multiple manufacturers have launched their generic version of AstraZeneca’s Daliresp for the treatment of chronic obstructive pulmonary disease (COPD). Daliresp generated $260 million in U.S. annual sales in 2021.

+Specialty medication



Related news


March 24, 2023

Look for Prime + Magellan Rx at AMCP 2023

Dr. Prerak Parikh (far left) and Dr. Sneha Sharma (far right) discuss trends…


March 23, 2023

Top female finance executive encourages DEI narrative

Over the past 30 years women’s careers in finance have seen significant progress,…


March 21, 2023

Top 10 acronyms in drug pipeline content, Part 2

News about biosimilars is everywhere. Sometimes you just need the basics. This four-part…